This study aimed to investigate such underdosing of enoxaparin and its potential impact on achieving therapeutic anti-Xa levels. Methods: This multicentric, retrospective, observational study included patients with acute ischemic stroke due to atrial fibrillation. All patients receiv...
ml.26,27 Though generally not measured, studies in adults will target prophylactic anti‐Xa levels with enoxaparin of 0.2–0.4 units/ml, when used.28–30 Unfortunately, a randomized controlled trial has yet to be completed to determine the efficacy of targeting a specific anti‐Xa level for ...
To describe the successful use of high-dose enoxaparin therapy (1.5 mg/kg subcutaneously twice daily) to attain a therapeutic anti-factor Xa (anti-Xa) level in a cancer patient with heparin resistance.A proven heparin-resistant patient with venous thromboembolism (VTE) and lung cancer who require...
Gruner, S. et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 105, 1492–1499 (2005). PubMed Google Scholar Reimann, A. et al. Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatmen...
(Fig.2c). The first humanized mAb approved by the US FDA in 1997 was the anti-IL-2 receptor, daclizumab, for the prevention of transplant rejection (Fig.1) [11]. The humanization of antibodies made it possible to clinically apply a new class of biologics directed against diseases that ...
(anti-EGFR-IL-dox and U3-1402); (3) IGF1R blocking drugs (linsitinib, NVP-AEW541, and BMS-754807); (4) CXCR4 antagonists (balixafortide) and CXCR4-binding peptide (DV1); (5) Src inhibitors (dasatinib and BJ-2302); (6) MEK inhibitors (trametinib and binimetinib); (7) ERK ...
[196]. As an oncolytic adenovirus, Delta-24-RGD, engineered to selectively replicate in and destroy cancer cells, shows promising anti-glioma effects by enhancing the anticancer immune response [197,198,199]. Delta-24-RGD downregulates IDO expression in glioma cells and Foxp3 levels in Tregs, ...
Extensive research on the CXCL12-CXCR4 axis in acute myeloid leukemia (AML) has resulted in the incorporation of novel anti-leukemia drugs targeting this axis into therapeutic strategies. However, despite this progress, a comprehensive and up-to-date review addressing the role of the CXCL12-CXCR4...
As DNase1 seems to have no relevant side effects, it thus might be suitable for neonates requiring anti-thrombotic treatment. However, systemic DNase1 treatment has only been administered in adult lupus patients and has yet to be studied in neonates27. Based on these study’s findings, which ...
Four different rivaroxaban calibrated anti-Xa assays had R2values >0.98, demonstrating strong correlations with rivaroxaban drug levels. In conclusion, PT, aPTT and ACT are often normal in patients on therapeutic doses of rivaroxaban. However, PT and ACT may have clinical utility at higher drug ...